A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial With an Open-Label Extension Phase of Perampanel as Adjunctive Treatment in Subjects at Least 2 Years of Age With Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome

Trial Profile

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial With an Open-Label Extension Phase of Perampanel as Adjunctive Treatment in Subjects at Least 2 Years of Age With Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome

Recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Jul 2017

At a glance

  • Drugs Perampanel (Primary)
  • Indications Lennox-Gastaut syndrome
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Eisai Inc
  • Most Recent Events

    • 15 Mar 2017 Planned End Date changed from 1 Aug 2020 to 1 Feb 2020.
    • 15 Mar 2017 Planned primary completion date changed from 1 Aug 2019 to 1 Feb 2019.
    • 28 Oct 2016 Status changed from not yet recruiting to recruiting, as per Eisai media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top